Atlas Trials

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Clinical trial NCT05021770 · UNKNOWN

Trial details

NCT number
NCT05021770
Sponsor
Huiqiang Huang
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Refractory and Relapsed Primary CNS LymphomaPCNSLNon Hodgkin Lymphoma
Start date
2021-12-01
Primary completion
2022-12-01
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.